Full Year 2025 Trading Update

About this update from Santhera Pharmaceuticals Holding Ag

Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2025. Dario Eklund, CEO of Santhera, said: “The strong commercial momentum we are seeing with AGAMREE® reflects growing adoption across our core European markets and through our global partners, expanding access for more patients with Duchenne muscular dystrophy worldwide. As we continue to broaden our geographic footprint, strategic partnerships such as the Nxera agreement, signed in January and covering Japan and certain other APAC markets, are extending our reach into important new territories and strengthening our ability to scale access sustainably. Combined with positive long-term data from up to eight years of AGAMREE treatment, demonstrating an improved safety profile while maintaining efficacy comparable to standard-of-care corticosteroids, we believe Santhera is well positioned to build on this momentum as we continue to execute our strategy of building a leading rare disease company.” Key unaudited financials for 2025 Operational Highlights Guidance for 2026 Upcoming Events About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Commission (EC), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in Switzerland by Swissmedic, in China by the National Medical Products Administration (NMPA), in Hong Kong by the Department of Health (DoH) and in Canada by Health Canada. Santhera has out-licensed the rights to AGAMREE as follows: to Catalyst Pharmaceuticals for North America; to Sperogenix Therapeutics for China and certain countries in Southeast Asia; and to Nxera Pharma for Japan, South Korea, Australia, and New Zealand. For further information, please visit www.santhera.com . AGAMREE® is a trademark of Santhera Pharmaceuticals. For further information, please contact: Santhera Catherine Isted, Chief Financial Officer  [email protected] ICR Healthcare:  [email protected] Stifel                                                                                               +44 (0)20 7710 7600 Brough Ransom, Charles Hoare, Fred Walsh Octavian                                                                                             +41 (0)44 520 1588 Serge Monnerat, Marius Zuberbuehler Disclaimer / Forward-looking Statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment

View stock analysis, news, and events for Santhera Pharmaceuticals Holding Ag